Immune Therapeutics, Inc. Announces Exclusive Agreement for Sale of Lodonal in Kenya Valued at Over $31 Million ORLANDO, Fla., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a specialty pharmaceutical company focused on developing and commercializing Lodonal™, its patented,...

Immune Therapeutics Retains Investor Relations Partners to Support Company’s Strategic IR Program as it Prepares for Commercialziation ORLANDO, Fla., Jan. 26, 2017 (GLOBE NEWSWIRE) -- Investor Relations Partners (IRP), one of the fastest growing investor and public relations firms in the nation, today announced that Immune...

Investor Relations Partners Places Two Major Media Stories for Newest Clients; IRP Discusses Keys to Its Extraordinary Client Success LOS ANGELES, Aug. 02, 2016 (GLOBE NEWSWIRE) -- Investor Relations Partners, Inc. (“IRP”), a full-service investor relations firm serving a global client base, today reported its media relations...